MarginsXMarginsX
Home › Markets › Health Care › SHPH

Shuttle Pharmaceuticals Holdings Inc. (SHPH)

SHPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.24
-6.40% on the day
Market cap
$20.2M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerSHPH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001757499

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
0.2 months
$90K cash at June 30, 2026
Share count, 1 year
+4349.8%
2025-08-11 to 2026-09-21 · +60468.8% over 3 years
Going-concern doubt
Yes
10-Q filed September 24, 2026
Insider net buying, 12 months
-$323K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements contained in this report are issued."
10-Q 2026-09-24
Cash and burn$90K cash; operating cash flow -$1.6M a quarter.Report 2026-06-30
Shares outstanding4,764,696 (2026-09-21); 1,070,773 a year earlier; 15,733,165 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-2000 overall).Cover page 2026-09-21
Reverse splits, 3 years3; latest 1-for-10 on 2026-06-11Source 2026-06-11
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-08-28
AuditorForvis Mazars, LLP, Atlanta, Georgia, United States; changed auditors 2 times in 24 months8-K 4.01 2026-11-06
Late filings, 12 months1 NT noticeNT 10-Q 2026-08-17
Insider trades, 12 monthsBought $182K, sold $505K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.1M-$568K$90KNo debt tagsNeeds four quarters10-Q 2026-09-24
Q1 2026
2026-03-31
Not filed-$2.2M-$2.4M$1.1MNo debt tagsNeeds four quarters10-Q 2026-09-24
Q4 2025
2025-12-31
Not filed-$2.6M-$973K$334KNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$2.3M-$2.6M$2.1MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$3.7M-$3.4M$4.8M$10.0MNeeds four quarters10-Q 2026-09-24
Q1 2025
2025-03-31
Not filed-$3.1M-$2.5M$4.5M$10.0MNeeds four quarters10-Q 2026-09-24
Q4 2024
2024-12-31
Not filed-$1.6M-$2.7M$1.9M$10.2MNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$3.8M-$2.0M$157K$10.0MNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-18.9%
1 month-12.5%
3 months-1.1%
Year to date-74.8%
1 year-80.4%
From 52-week high-81.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CELUCelularity Inc.$0.6191-1.75%$20.1M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
TXMDTherapeuticsMD Inc.$1.81-3.21%$20.9M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
LPCNLipocine Inc.$1.66-2.92%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier